CervoMed financials
$2.97+3.13%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M |
| Gross profit | $4.0M | $9.7M | $7.1M |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Operating income | -$28.3M | -$18.2M | -$7.8M |
| Net income | -$27.0M | -$16.3M | -$2.2M |
| Net margin | −673.1% | −167.3% | −30.4% |
| Diluted EPS | $-2.98 | $-2.02 | $-0.82 |
| EBITDA | -$28.3M | -$18.2M | -$7.8M |
| Operating cash flow | -$23.4M | -$16.5M | -$7.4M |
| Free cash flow | -$23.4M | -$16.5M | -$7.4M |
| Diluted shares | 9.0M | 8.1M | 2.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $8.2M | $9.0M | $7.8M |
| Short-term investments | $12.6M | $29.9M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $22.9M | $43.1M | $10.0M |
| Total liabilities | $4.7M | $3.9M | $2.6M |
| Shareholders' equity | $18.2M | $39.2M | $7.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology